These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A. Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506 [Abstract] [Full Text] [Related]
5. A comparison of the Cohen-Mansfield agitation inventory with the CERAD behavioral rating scale for dementia in community-dwelling persons with Alzheimer's disease. Weiner MF, Koss E, Patterson M, Jin S, Teri L, Thomas R, Thal LJ, Whitehouse P. J Psychiatr Res; 1998 Oct; 32(6):347-51. PubMed ID: 9844950 [Abstract] [Full Text] [Related]
7. Improvement in behavioral symptoms and advance of activity acrophase after short-term bright light treatment in severe dementia. Skjerve A, Holsten F, Aarsland D, Bjorvatn B, Nygaard HA, Johansen IM. Psychiatry Clin Neurosci; 2004 Aug; 58(4):343-7. PubMed ID: 15298644 [Abstract] [Full Text] [Related]
8. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, Paul SM. Alzheimer Dis Assoc Disord; 1997 Aug; 11 Suppl 4():S16-22. PubMed ID: 9339268 [Abstract] [Full Text] [Related]
9. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598 [Abstract] [Full Text] [Related]
18. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication. Forester B, Vanelli M, Hyde J, Perez R, Ahokpossi C, Sribney W, Adkison L. Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660 [Abstract] [Full Text] [Related]